source
- Belgian startup Armed Cell Therapeutics acquires Galapagos-derived CAR-T assets for €8 million upfrontArmed Cell Therapeutics, a new Belgian biotech chaired by former Galapagos CEO Paul Stoffels, has taken ownership of several cell therapy programs previously held by Lakefront Biotherapeutics. The…
- OrbiMed raises $3 billion, its biggest Asian fund yet, to boost biotech investments worldwideOrbiMed announced it has closed a $3 billion fundraising round, the largest ever for its Asia‑focused vehicle. The capital will be used to make new growth‑equity and venture investments in biotech…